Volv Global is pleased to be participating in the Life Sciences Innovation & Investment Corridor between Lausanne & London, hosted at ARC West London in Hammersmith on 29 April 2026. Organised by Innovaud in association with One Nucleus and ARC West London, the event brings together key life sciences stakeholders from the Swiss Health Valley and the London–Cambridge corridor to explore bilateral innovation and investment opportunities across two of Europe’s most significant life science ecosystems.
Two ecosystems, one conversation
The Lausanne region sits at the heart of Switzerland’s Health Valley, an ecosystem of more than 1,200 companies spanning pharma, biotech, medtech, diagnostics, drug discovery and data science, alongside world-leading academic institutions including EPFL, and innovation parks including Biopôle Lausanne – where Volv Global is based. One Nucleus is the not-for-profit life sciences and healthcare membership organisation at the heart of Europe’s largest life science cluster, spanning London and Cambridge. ARC West London, located on the banks of the Thames in Hammersmith, is one of Europe’s leading science and innovation campuses, home to over 300 organisations working across life sciences, pharmaceuticals and deep tech.
The event is designed to open and deepen connections between these two ecosystems – creating the conditions for partnerships that can translate scientific and commercial potential into real impact for patients and the companies that serve them.
Volv Global at the event
Volv Global CEO and founder Christopher Rudolf will represent the company at the event. With production-deployed partnerships across the UK, USA, Germany and the Netherlands, and a decade of applied machine learning in rare and difficult-to-diagnose disease, Christopher brings a perspective grounded in what this kind of cross-ecosystem collaboration can produce in practice – across clinical development, market access, HEOR and commercial strategy.
For pharmaceutical companies and life sciences organisations attending, Christopher will be available to discuss how Volv Global’s work with leading pharma partners has generated real-world evidence, surfaced undiagnosed patient populations, and informed decisions across the product lifecycle. The conversation this event is designed to facilitate – connecting ambitious, internationally operating innovators with pharma partners and the networks they need to scale – is one that Volv Global knows well from its own experience.
About the event
The Life Sciences Innovation & Investment Corridor: Lausanne & London is organised by Innovaud in association with One Nucleus and ARC West London.
- Date: Wednesday, 29 April 2026
- Time: 16:30 – 19:00
- Location: ARC West London, Hammersmith, London
- Register: https://lu.ma/vzkavn6q
If you are attending and would like to arrange a meeting with Christopher, please contact us.
About the organisers
Innovaud is the investment promotion agency for the Canton of Vaud, Switzerland, supporting international companies looking to establish or expand their presence in the Lausanne region and the wider Swiss Health Valley.
One Nucleus is a not-for-profit life sciences and healthcare membership organisation headquartered in Cambridge, supporting institutions, companies and individuals across the London–Cambridge corridor through connectivity, events, training and international programmes.
ARC West London is part of Advanced Research Clusters (ARC), Europe’s leading network of science and innovation clusters. Located in Hammersmith on the banks of the Thames, ARC West London is home to over 300 science and innovation organisations and offers state-of-the-art laboratory, research and development space.
Frequently Asked Questions
What is the Life Sciences Innovation & Investment Corridor: Lausanne & London?
An evening event in Hammersmith bringing together life sciences stakeholders from the Swiss Health Valley – including organisations from Innovaud, EPFL Innovation Park and Biopôle Lausanne – with members of One Nucleus and ARC West London, to explore bilateral innovation and investment opportunities across the two ecosystems.
Who is representing Volv Global at the event?
Volv Global CEO and founder Christopher Rudolf will be attending and is available to meet with pharmaceutical companies and life sciences organisations interested in learning more about Volv Global’s work.
Why is Volv Global participating in this event?
The Lausanne–London life sciences corridor connects two ecosystems where Volv Global already operates and has established partnerships. Events like this are where the clinical development, market access and commercialisation conversations that matter to our pharma partners begin – and where the value of the Swiss Health Valley as a home for internationally operating AI healthcare companies becomes visible.
How can I arrange a meeting with Volv Global at the event?
Please contact us ahead of 29 April and we will be glad to arrange a time to connect.
